Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Huanpeng ChenYuying YangYuqing DengFengjiao WeiQingyu ZhaoYongqi LiuZhonghua LiuBolan YuZhaofeng HuangPublished in: Journal for immunotherapy of cancer (2022)
In summary, our findings indicate that CD47 blocker SIRPα-Fc enhances the antitumor efficacy of CAR-T cells and propose to block CD47/SIRPα signaling effect on CAR-T cells function, which could provide a new strategy for successful cancer immunotherapy by rationalizing combination of CD47 blocker and CAR-T cell therapy.